Paper Details

  1. Home
  2. Paper Details

A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.

Author: , AndoKaoru, ArimotoTakanori, DaidojiHyuma, HironoOsamu, IkenoEiichiro, KubotaIsao, MatsuiMotoyuki, MiyamotoTakuya, MiyashitaTakehiko, MiyawakiHiroshi, NishiyamaSatoshi, OtakiYoichiro, ShishidoTetsuro, SugawaraShigeo, TakahashiHiroki, WatanabeTetsu, YashiroYoshinori

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated whether adding eicosapentaenoic acid (EPA) to high-dose pitavastatin (PTV) could reinforce coronary plaque regression and stabilization. Further research is needed to determine the clinical significance of this approach.
Paper Details　
Original Abstract of the Article :
There is a residual risk of coronary heart disease (CHD) despite intensive statin therapy for secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by the addition of eicosapentaenoic acid (EPA) to high-dose pitavastatin (P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jjcc.2017.07.007

データ提供：米国国立医学図書館（NLM）

Reducing the Risk of Heart Disease: A Study on Eicosapentaenoic Acid

The study explores the potential benefit of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, in addition to statin therapy for secondary prevention of coronary heart disease (CHD). Imagine a camel caravan traversing a desert filled with hidden dangers. Statin therapy is like a reliable camel, protecting against heart disease, but additional measures are needed to safeguard against residual risks. This study investigates whether EPA, like a resourceful oasis, can further reinforce protective measures and contribute to plaque regression and stabilization.

EPA: A Potential Ally in Heart Health

The study's aim was to determine if EPA could complement high-dose pitavastatin (PTV) in reducing CHD risk. The results of this study, while promising, underscore the need for further research to solidify EPA's role in heart health. Like a desert explorer carefully mapping out new territory, researchers continue to explore the full potential of EPA and its impact on heart disease.

A Healthy Dose of Omega-3s

While this study suggests potential benefits of EPA in reducing CHD risk, it's important to consult with a healthcare professional before making any changes to your diet or supplements. Just as a traveler needs to be aware of the desert's harsh conditions, it's crucial to approach heart health with informed decisions and expert guidance. Maintaining a balanced diet, regular exercise, and seeking regular checkups are key factors in promoting overall cardiovascular well-being.

Dr. Camel's Conclusion

This study offers an intriguing glimpse into the potential role of EPA in reducing residual risk of heart disease. While further research is needed, the findings suggest that EPA, like a helpful oasis, may provide additional support for heart health. It's important to remember that a balanced lifestyle and informed decisions, guided by healthcare professionals, are crucial for maintaining a healthy heart.

Date :
  1. Date Completed 2018-04-23
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28863874

DOI: Digital Object Identifier

10.1016/j.jjcc.2017.07.007

Related Literature

Article Analysis
・Side Effects of pitavastatin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.